×

COPYRIGHT(C) 2022 AEVISBIO, INC. ALL RIGHTS RESERVED.

 

  • NEWS
  • Press Release

Press Release

Publication Notice

2020-09-14

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife (June 26, 2020).

The study, titled, “3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation,” may be found here (https://elifesciences.org/articles/54726).